Japanese Encephalitis: Control Measures and Challenges

Japanese Encephalitis (JE) is a mosquito-borne viral infection that affects millions of people across Asia and the Western Pacific. It’s a disease that often goes unnoticed because most infections cause no symptoms-but when it strikes with full force, the consequences can be devastating, especially for children. Understanding how this disease spreads, manifests, and the strategies we use to control it can equip healthcare professionals and communities to better protect vulnerable populations.

What is Japanese Encephalitis? 🔗

Japanese Encephalitis is caused by the Japanese Encephalitis Virus (JEV), a flavivirus closely related to dengue, yellow fever, and West Nile viruses. The disease was first documented in Japan in 1871, and the virus was isolated in 1935 from the brain of a fatal encephalitis case. Today, JEV remains the leading cause of viral encephalitis in Asia, affecting an estimated 100,000 people clinically each year.

Twenty-four countries in the WHO South-East Asia and Western Pacific Regions have endemic JEV transmission, putting over 3 billion people at risk. The disease primarily impacts rural and agricultural areas, particularly regions with rice paddies and pig farming-environments that support the virus’s transmission cycle.

How does transmission occur? 🔗

JEV follows an enzootic cycle, meaning it circulates between mosquitoes, pigs, and water birds. The primary vector is Culex tritaeniorhynchus, a mosquito species that breeds prolifically in rice fields and stagnant water. Pigs serve as amplifying hosts, developing high levels of viremia that efficiently infect mosquitoes. Water birds such as egrets and herons also maintain the virus in nature.

Humans become infected when bitten by mosquitoes carrying the virus. However, humans are considered “dead-end hosts”-the virus doesn’t multiply sufficiently in human blood to infect other mosquitoes. This means human-to-human transmission through mosquitoes doesn’t occur. Transmission tends to peak during the monsoon and post-monsoon periods when mosquito breeding intensifies.

Clinical manifestations and symptoms 🔗

The vast majority of JEV infections are asymptomatic or cause only mild illness. According to the CDC, more than 99% of infected individuals experience no symptoms or only mild symptoms like fever and headache. However, approximately 1 in 250 infections progresses to severe neurological disease.

The incubation period ranges from 4 to 15 days. When symptomatic disease develops, it typically begins with sudden onset of high fever, severe headache, and vomiting. In children, gastrointestinal symptoms may dominate initially. Over the following days, the infection can rapidly progress to more alarming signs.

Progression to encephalitis 🔗

When the virus crosses the blood-brain barrier and invades the central nervous system, encephalitis develops. Patients may show mental status changes, disorientation, confusion, and agitation. Seizures are common, particularly in children. The classical description of JE includes Parkinsonian features-mask-like facial expression, tremors, cogwheel rigidity, and abnormal movements.

Neck stiffness indicates meningeal irritation, while spastic paralysis may affect various muscle groups. Body temperature can rise dramatically, sometimes reaching 38-43°C. Acute flaccid paralysis similar to poliomyelitis has also been documented in some cases. Without supportive care, the condition can deteriorate to coma and death.

Neurological complications and long-term outcomes 🔗

The case-fatality rate among those who develop encephalitis can reach 30%, and death occurs more frequently in children under five years, immunocompromised individuals, and the elderly. But even survival doesn’t guarantee full recovery.

Among survivors, 30-50% experience permanent neurological, cognitive, or behavioural sequelae. These complications include hearing loss, vision impairment, speech and language difficulties, memory problems, and motor weakness. A study from Assam, India found that 21.3% of confirmed JE patients had neurological sequelae at discharge, while some continued experiencing seizures long after the acute phase.

Impact on children 🔗

Children bear the greatest burden of JE. The disease predominantly affects those under 15 years of age, and younger children often face worse outcomes. Fixed flexion deformities of arms and hyperextension of legs are common long-term physical consequences. About 20% of survivors experience severe cognitive and language impairment, usually accompanied by motor problems.

More subtle sequelae-learning difficulties, behavioural problems, and subtle neurological signs-may affect even those initially categorized as having “good recovery.” This underscores the need for long-term follow-up and rehabilitation services for JE survivors.

Control measures for Japanese Encephalitis 🔗

Controlling JE requires a multipronged approach combining vaccination, surveillance, and vector management. Since there is no specific antiviral treatment, prevention remains the cornerstone of JE control.

Vaccination programmes 🔗

Vaccination is the most effective strategy for preventing JE. WHO recommends integrating JE vaccine into national immunization schedules wherever the disease is a public health priority. Three main vaccine types are currently available: inactivated Vero cell-derived vaccines, live attenuated vaccines, and live recombinant (chimeric) vaccines.

In India, vaccination efforts have expanded significantly since the devastating 2005 outbreak in Uttar Pradesh and Bihar that killed over 1,500 people. JE vaccination gradually expanded from 11 districts in 4 states to 269 districts in 21 states between 2011 and 2018. The government has targeted nearly all districts for eventual coverage. Adult vaccination has also been initiated in high-prevalence states like Assam, West Bengal, and Uttar Pradesh.

Sentinel surveillance and epidemiological monitoring 🔗

Effective surveillance is critical for early detection and rapid response. India’s National Vector Borne Disease Control Programme (NVBDCP) has established surveillance guidelines for reporting Acute Encephalitis Syndrome (AES) cases. Sentinel surveillance sites-some with laboratory facilities and others without-form a network that monitors and reports suspected and confirmed JE cases.

Laboratory diagnosis typically relies on detecting JEV-specific IgM antibodies in cerebrospinal fluid or serum. However, diagnostic capacity varies across regions, and many cases go unconfirmed due to limited laboratory access in rural areas.

Vector control strategies 🔗

Mosquito control measures include larval source reduction, insecticide spraying, and promoting use of insecticide-treated bed nets. Community-based initiatives and awareness campaigns help reduce breeding sites by eliminating stagnant water around homes. However, the European Centre for Disease Prevention and Control notes that in endemic areas, vaccination of humans should be prioritized over vector control, as evidence supporting reduction in disease burden from mosquito control alone is limited.

Personal protective measures remain important, especially for those in endemic areas. These include using mosquito repellents, wearing long-sleeved clothing, and avoiding outdoor activities during peak mosquito activity at dusk and dawn.

Challenges in controlling Japanese Encephalitis 🔗

Despite progress, several challenges continue to hamper JE control efforts across endemic countries.

Incomplete reporting and surveillance gaps 🔗

A CDC review found that challenges remain, including incomplete case reporting, misclassification of cases, and inadequate monitoring of vaccination coverage. Only about 10% of estimated global JE cases are actually reported to WHO, meaning the true disease burden is likely much higher than official figures suggest.

In India, AES surveillance remains insufficient, and the actual disease burden, distribution, and trends are still not fully understood. Many AES cases are never confirmed for JE, and other aetiologies-including scrub typhus, enteroviruses, and dengue-may be responsible for encephalitis cases previously attributed to unknown causes.

Expansion to non-endemic areas 🔗

JE is emerging in previously non-endemic regions. A 2022 case in Pune, Maharashtra-traditionally not an endemic zone-raised concerns about potential outbreaks in urban areas with suitable mosquito breeding conditions and pig populations. Such emergence in new territories demands heightened vigilance and rapid response capabilities.

Agricultural and environmental factors 🔗

Intensified rice cultivation and irrigation expansion have been linked to increased JEV transmission. Research indicates that population growth, agricultural development, and pig rearing without adequate vaccination programmes may increase transmission in countries like Bangladesh, Cambodia, and Myanmar. These factors create ideal conditions for mosquito breeding and virus amplification.

Resource constraints and healthcare access 🔗

Managing JE requires significant resources-for vaccination, surveillance, laboratory diagnostics, and rehabilitation of survivors. Many affected regions lack sufficient healthcare infrastructure. Endemic areas are predominantly rural with limited access to medical facilities capable of providing intensive supportive care for encephalitis patients. Long-term rehabilitation services for survivors with neurological sequelae are often unavailable.

The path forward 🔗

Sustained commitment, adequate funding, and intersectoral collaboration are essential for controlling JE. Strengthening vaccination coverage, improving surveillance systems, and investing in laboratory capacity will help reduce the disease burden. Community education about preventive measures and early recognition of symptoms can facilitate timely medical attention.

For nursing professionals, understanding JE is vital-whether working in endemic regions or caring for patients who have travelled to high-risk areas. Recognizing the clinical presentation, providing supportive care, and educating communities about prevention can all contribute to reducing the impact of this potentially devastating disease.

What do you think? How can healthcare systems in endemic regions better address the long-term rehabilitation needs of JE survivors, and what role can community health workers play in improving early detection and vaccination coverage?

References

1. https://www.who.int/news-room/fact-sheets/detail/japanese-encephalitis
2. https://www.cdc.gov/japanese-encephalitis/data-maps/index.html
3. https://www.cdc.gov/japanese-encephalitis/symptoms-diagnosis-treatment/index.html
4. https://www.ncbi.nlm.nih.gov/books/NBK470423/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC3891618/
6. https://www.medlink.com/articles/japanese-encephalitis
7. https://www.who.int/southeastasia/activities/accelerated-control-of-japanese-encephalitis
8. https://www.path.org/who-we-are/programs/center-for-vaccine-innovation-and-access/case-study-indias-leadership-in-the-fight-against-japanese-encephalitis/
9. https://ncvbdc.mohfw.gov.in/index1.php?lang=1&level=2&sublinkid=5926&lid=3760
10. https://www.ecdc.europa.eu/en/japanese-encephalitis/prevention-and-control
11. https://www.cdc.gov/mmwr/volumes/66/wr/mm6622a3.htm
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5644291/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10205214/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC2660690/